D
Bioventus Inc.
BVS
$9.51
$0.141.49%
D
Sell
5/17/2024Upgraded
Bioventus Inc. (BVS) was upgraded to D- from E+ on 5/17/2024 due to an increase in the volatility index, growth index and solvency index. EBIT increased 117.91% from $2.58M to $5.62M, and earnings per share increased from -$0.0966 to -$0.0721.
Bioventus Inc. (BVS) was upgraded to D- from E+ on 5/17/2024 due to an increase in the volatility index, growth index and solvency index. EBIT increased 117.91% from $2.58M to $5.62M, and earnings per share increased from -$0.0966 to -$0.0721.
E
Sell
5/3/2024Downgrade
Bioventus Inc. (BVS) was downgraded to E+ from D- on 5/3/2024 due to a decline in the volatility index and valuation index.
Bioventus Inc. (BVS) was downgraded to E+ from D- on 5/3/2024 due to a decline in the volatility index and valuation index.
D
Sell
7/27/2023Upgraded
Bioventus Inc. (BVS) was upgraded to D- from E+ on 7/27/2023 due to an increase in the volatility index and total return index.
Bioventus Inc. (BVS) was upgraded to D- from E+ on 7/27/2023 due to an increase in the volatility index and total return index.
E
Sell
7/12/2023Downgrade
Bioventus Inc. (BVS) was downgraded to E+ from D- on 7/12/2023 due to a decline in the volatility index.
Bioventus Inc. (BVS) was downgraded to E+ from D- on 7/12/2023 due to a decline in the volatility index.
D
Sell
6/26/2023Upgraded
Bioventus Inc. (BVS) was upgraded to D- from E+ on 6/26/2023 due to an increase in the volatility index and total return index.
Bioventus Inc. (BVS) was upgraded to D- from E+ on 6/26/2023 due to an increase in the volatility index and total return index.
E
Sell
5/23/2023Downgrade
Bioventus Inc. (BVS) was downgraded to E+ from D- on 5/23/2023 due to a major decline in the efficiency index, solvency index and growth index. Net income declined 335.8% from -$31.93M to -$139.15M, earnings per share declined from -$0.5156 to -$2.2398, and debt to equity increased from 1.33 to 2.38.
Bioventus Inc. (BVS) was downgraded to E+ from D- on 5/23/2023 due to a major decline in the efficiency index, solvency index and growth index. Net income declined 335.8% from -$31.93M to -$139.15M, earnings per share declined from -$0.5156 to -$2.2398, and debt to equity increased from 1.33 to 2.38.
D
Sell
4/6/2023Downgrade
Bioventus Inc. (BVS) was downgraded to D- from D on 4/6/2023 due to a decline in the solvency index, volatility index and efficiency index. Debt to equity increased from 1.25 to 1.33, total capital declined 5.38% from $821.14M to $776.92M, and the quick ratio declined from 0.58 to 0.56.
Bioventus Inc. (BVS) was downgraded to D- from D on 4/6/2023 due to a decline in the solvency index, volatility index and efficiency index. Debt to equity increased from 1.25 to 1.33, total capital declined 5.38% from $821.14M to $776.92M, and the quick ratio declined from 0.58 to 0.56.
D
Sell
4/3/2023Upgraded
Bioventus Inc. (BVS) was upgraded to D from D- on 4/3/2023 due to an increase in the volatility index and efficiency index.
Bioventus Inc. (BVS) was upgraded to D from D- on 4/3/2023 due to an increase in the volatility index and efficiency index.
D
Sell
3/14/2023Downgrade
Bioventus Inc. (BVS) was downgraded to D- from D on 3/14/2023 due to a decline in the volatility index and total return index.
Bioventus Inc. (BVS) was downgraded to D- from D on 3/14/2023 due to a decline in the volatility index and total return index.
D
Sell
1/4/2023Upgraded
Bioventus Inc. (BVS) was upgraded to D from D- on 1/4/2023 due to an increase in the volatility index.
Bioventus Inc. (BVS) was upgraded to D from D- on 1/4/2023 due to an increase in the volatility index.
D
Sell
12/16/2022Downgrade
Bioventus Inc. (BVS) was downgraded to D- from D on 12/16/2022 due to a substantial decline in the solvency index, efficiency index and total return index. Net income declined 1,392.62% from -$7.25M to -$108.25M, debt to equity increased from 0.84 to 1.25, and the quick ratio declined from 0.93 to 0.58.
Bioventus Inc. (BVS) was downgraded to D- from D on 12/16/2022 due to a substantial decline in the solvency index, efficiency index and total return index. Net income declined 1,392.62% from -$7.25M to -$108.25M, debt to equity increased from 0.84 to 1.25, and the quick ratio declined from 0.93 to 0.58.
D
Sell
3/2/2022Upgraded
Bioventus Inc. (BVS) was upgraded to D from D- on 3/2/2022 due to an increase in the valuation index.
Bioventus Inc. (BVS) was upgraded to D from D- on 3/2/2022 due to an increase in the valuation index.
D
Sell
11/3/2021Upgraded
Bioventus Inc. (BVS) was upgraded to D- from E on 11/3/2021 due to an increase in the efficiency index and solvency index.
Bioventus Inc. (BVS) was upgraded to D- from E on 11/3/2021 due to an increase in the efficiency index and solvency index.
E
Sell
8/13/2021Downgrade
Bioventus Inc. (BVS) was downgraded to E from E+ on 8/13/2021 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from -$0.0249 to -$0.0987, net income declined 116.55% from $24.94M to -$4.13M, and EBIT declined 90.44% from $25.19M to $2.41M.
Bioventus Inc. (BVS) was downgraded to E from E+ on 8/13/2021 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from -$0.0249 to -$0.0987, net income declined 116.55% from $24.94M to -$4.13M, and EBIT declined 90.44% from $25.19M to $2.41M.
E
Sell
8/2/2021Upgraded
Bioventus Inc. (BVS) was upgraded to E+ from E on 8/2/2021 due to an increase in the total return index.
Bioventus Inc. (BVS) was upgraded to E+ from E on 8/2/2021 due to an increase in the total return index.
E
Sell
5/14/2021None
Bioventus Inc. (BVS) was downgraded to E from U on 05/14/2021.
Bioventus Inc. (BVS) was downgraded to E from U on 05/14/2021.
NASDAQ
04/02/2025 4:00PM Eastern
Quotes delayed
